lactic acid has been researched along with Whooping Cough in 4 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Whooping Cough: A respiratory infection caused by BORDETELLA PERTUSSIS and characterized by paroxysmal coughing ending in a prolonged crowing intake of breath.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Presentation of pertussis toxoid as nano/micro particles (NP/MP) gave similar antigen-specific IgG responses in mice compared to soluble antigen." | 1.43 | PLGA nano/micro particles encapsulated with pertussis toxoid (PTd) enhances Th1/Th17 immune response in a murine model. ( Asokanathan, C; Khaing, KK; Kmiec, D; Kong, D; Li, P; Liu, F; Song, B; Wei, X; Xing, D, 2016) |
| "Purified Bordetella pertussis antigens, encapsulated in biodegradable poly(DL-lactide-co-glycolide) (DL-PLG) microspheres, were evaluated for their immunogenicity and ability to elicit a protective immune response against B." | 1.29 | Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres. ( Eldridge, J; Gilley, R; Hudson, M; Leef, M; Shahin, R, 1995) |
| "Fimbriae from Bordetella pertussis have been encapsulated in poly(lactide-co-glycolide) microparticles of a size appropriate for uptake by the immune inductive tissues of the gastrointestinal tract." | 1.29 | Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection. ( Farrar, GH; Jones, DH; McBride, BW; O'Hagan, DT; Robinson, A; Thornton, C, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, P | 1 |
| Asokanathan, C | 1 |
| Liu, F | 1 |
| Khaing, KK | 1 |
| Kmiec, D | 1 |
| Wei, X | 1 |
| Song, B | 1 |
| Xing, D | 1 |
| Kong, D | 1 |
| Shahin, R | 1 |
| Leef, M | 1 |
| Eldridge, J | 1 |
| Hudson, M | 1 |
| Gilley, R | 1 |
| Jones, DH | 1 |
| McBride, BW | 1 |
| Thornton, C | 1 |
| O'Hagan, DT | 1 |
| Robinson, A | 1 |
| Farrar, GH | 1 |
| Conway, MA | 1 |
| Madrigal-Estebas, L | 1 |
| McClean, S | 1 |
| Brayden, DJ | 1 |
| Mills, KH | 1 |
4 other studies available for lactic acid and Whooping Cough
| Article | Year |
|---|---|
PLGA nano/micro particles encapsulated with pertussis toxoid (PTd) enhances Th1/Th17 immune response in a murine model.
Topics: Animals; Antigens, Bacterial; Bordetella pertussis; Cell Line; Female; Immunoglobulin G; Interferon- | 2016 |
Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres.
Topics: Adjuvants, Immunologic; Administration, Intranasal; Animals; Antigens, Bacterial; Bacterial Outer Me | 1995 |
Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection.
Topics: Administration, Oral; Animals; Bordetella pertussis; Female; Fimbriae, Bacterial; Immunization; Immu | 1996 |
Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells.
Topics: Adhesins, Bacterial; Administration, Oral; Animals; Antibodies, Bacterial; Antigens, Bacterial; Bioc | 2001 |